The last decade has seen transcatheter aortic valve implantation （TAVI） emerge as the standard of care for patients with severe symptomatic aortic stenosis deemed to be either at excessiveor high-risk for surgical a...The last decade has seen transcatheter aortic valve implantation （TAVI） emerge as the standard of care for patients with severe symptomatic aortic stenosis deemed to be either at excessiveor high-risk for surgical aortic valve replacement （SAVR）. This position is supported by three important multicentre randomized trials comparing TAVI to the historical gold standard therapies： （1） The Placement of AoRTic TraNscathetER Valve Trial Edwards SAPIEN Transcatheter Heart Valve （PARTNER） IB Trial compared TAVI （Edwards SAPIEN, Edwards Lifesciences Inc., Irvine, CA） to optimal medical therapy in patients at excessive surgical risk, and demonstrated an absolute mortality reduction of 〉 20% at 1-year, an effect that was maintained out to 5-year follow-up;Ill （2） The PARTNER 1A Trial compared TAVI （Edwards SAPIEN, Edwards Lifesciences Inc.,展开更多
文摘The last decade has seen transcatheter aortic valve implantation （TAVI） emerge as the standard of care for patients with severe symptomatic aortic stenosis deemed to be either at excessiveor high-risk for surgical aortic valve replacement （SAVR）. This position is supported by three important multicentre randomized trials comparing TAVI to the historical gold standard therapies： （1） The Placement of AoRTic TraNscathetER Valve Trial Edwards SAPIEN Transcatheter Heart Valve （PARTNER） IB Trial compared TAVI （Edwards SAPIEN, Edwards Lifesciences Inc., Irvine, CA） to optimal medical therapy in patients at excessive surgical risk, and demonstrated an absolute mortality reduction of 〉 20% at 1-year, an effect that was maintained out to 5-year follow-up;Ill （2） The PARTNER 1A Trial compared TAVI （Edwards SAPIEN, Edwards Lifesciences Inc.,
